WO2009087218A1 - Thiazoltriazoles et thiazolimidazoles comme antagonistes du récepteur mglur5 - Google Patents

Thiazoltriazoles et thiazolimidazoles comme antagonistes du récepteur mglur5 Download PDF

Info

Publication number
WO2009087218A1
WO2009087218A1 PCT/EP2009/050215 EP2009050215W WO2009087218A1 WO 2009087218 A1 WO2009087218 A1 WO 2009087218A1 EP 2009050215 W EP2009050215 W EP 2009050215W WO 2009087218 A1 WO2009087218 A1 WO 2009087218A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
galkyl
methyl
salt
ghaloalkyl
Prior art date
Application number
PCT/EP2009/050215
Other languages
English (en)
Inventor
Pier Luca D'alessandro
Olivier Eric Lorthioir
Stephen Paul Watson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2009087218A1 publication Critical patent/WO2009087218A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • THIAZOLTRIAZOLES AND THIAZOLIMIDAZOLES AS ANTAGONISTS OF THE MGLUR5 RECEPTOR
  • This invention relates to novel thiazolotriazole and thiazoloimidazole derivatives.
  • the invention also relates to the use of the derivatives in treating diseases and conditions in which antagonism of the mGluRs receptor is beneficial, in particular substance related disorders.
  • the invention relates to compositions containing the derivatives and processes for their preparation.
  • the invention provides a compound of formula (I) or a salt thereof
  • R x or RY is -(CH 2 ) n R 6 , -CH 2 -OR 6 or -CH 2 -N(H)-R 6 , wherein R 6 is 5- or 6- membered monocyclic heteroaryl or phenyl, any of which is optionally substituted by one or more substituents independently selected from the list: halo, C- ⁇ galkyl, C-
  • R 1 a , R 1 b , R 4a , R 4b , R 6a , R 6b , R 7a and R 7b which may be the same or different, are H or C-
  • R 1 c , R 1 d , R 4c R 4d , R 6c , R 6d , R 7c and R 7d which may be the same or different, are H or C-
  • R7e which may be the same or different, are C-
  • R 1 , R 2 and R 3 are not all H.
  • an alkyl substituent is a univalent radical derived by removal of a hydrogen atom from an acyclic alkane.
  • .galkyl refers to such an alkyl substituent containing 1 to 6 carbons.
  • alkyl substituents include methyl and ethyl, may be straight chain (i.e. n-propyl, n-butyl, n- pentyl and n-hexyl) or branched chain (for example, isopropyl, isobutyl, secbutyl, tert- butyl, isopentyl and neopentyl).
  • such an alkyl substituent is methyl, ethyl, n-propyl or isopropyl.
  • a halo substituent refers to fluoro, chloro, bromo and iodo radicals. In an embodiment unless otherwise indicated such a halo substituent is fluoro or chloro.
  • a haloalkyl substituent is an alkyl group substituted by one or more halo substituents, which halo substituents may be the same or different.
  • .ghaloalkyl refers to such a haloalkyl substituent containing 1 to 6 carbons.
  • Such haloalkyl substituents include monofluoromethyl, difluoromethyl, trifluoromethyl and 1-chloro-2-fluoroethyl.
  • such a haloalkyl substituent is monofluoromethyl, difluoromethyl or trifluoromethyl.
  • an alkoxy substituent is group of formula "R-O-" where R is alkyl as defined above.
  • .galkoxy refers to such an alkoxy substituent containing 1 to 6 carbons.
  • alkoxy substituents include methoxy and ethoxy and may be straight chain (i.e. n-propoxy, n-butoxy, n-pentoxy and n-hexyloxy) or branched chain (for example, isopropoxy, isobutoxy, secbutoxy, tert-butoxy, isopentoxy and neopentoxy).
  • such an alkoxy substituent is methoxy, ethoxy, n-propoxy or isopropoxy.
  • an alkylthio substituent is group of formula "R-S-" where R is alkyl as defined above.
  • R is alkyl as defined above.
  • .galkylthio refers to such an alkylthio substituent containing 1 to 6 carbons.
  • alkylthio substituents include methylthio and ethylthio and may be straight chain or branched chain.
  • such an alkylthio substituent is methylthio, ethylthio, n-propylthio or isopropylthio.
  • a haloalkoxy substituent is a group of formula "R-O-" where R is haloalkyl as defined above.
  • R is haloalkyl as defined above.
  • C- ⁇ ghaloalkoxy refers to such a haloalkoxy substituent containing 1 to 6 carbons.
  • Such haloalkoxy substituents include monofluoromethoxy, difluorom ethoxy, trifluoromethoxy and 1- chloro-2-fluoroethoxy and may be straight chain or branched chain.
  • such a haloalkoxy substituent is monofluoromethoxy, difluoromethoxy or trifluoromethoxy.
  • a haloalkylthio substituent is a group of formula "R-S-" where R is haloalkyl as defined above.
  • R is haloalkyl as defined above.
  • C- ⁇ ghaloalkylthio refers to such a haloalkylthio substituent containing 1 to 6 carbons.
  • Such haloalkylthio substituents include monofluoromethylthio, difluoromethylthio, trifluoromethylthio and 1-chloro-2-fluoroethylthio and may be straight chain or branched chain.
  • such a haloalkylthio substituent is monofluoromethylthio, difluoromethylthio or trifluoromethylthio.
  • a cycloalkyl substituent is a univalent radical derived by removal of a hydrogen atom from a monocyclic cycloalkane, comprising from 3 to 6 carbons all interconnected to form a ring.
  • Examples of cycloalkyl substituents are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • the cycloalkyl substituent is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • a 5 to 6-membered monocyclic heterocyclyl substituent refers to a univalent radical derived by removal of a hydrogen atom from a 5 to 6-membered monocyclic heterocyclic ring; the heterocyclic ring containing one or more carbon atoms; one or more hydrogen atoms; and independently 1 to 4 heteroatoms such as nitrogen, oxygen and sulfur; the carbon and heteroatoms being interconnected to form a ring.
  • the monocyclic heterocyclyl substituent may be saturated, unsaturated or aromatic.
  • saturated monocyclic heterocyclyl substituents are pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperidinyl, dioxanyl, morpholino, dithianyl, thiomorpholino and piperazinyl.
  • unsaturated monocyclic heterocyclyl substituents are 2H-pyrrolyl, 2-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl and 2H- pyranyl, 4H-pyranyl.
  • aromatic monocyclic heterocyclyl substituents are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, azepinyl, oxazepinyl, thiazepinyl and diazepinyl.
  • a 5 to 6-memebered monocyclic heteroaryl substituent refers to a univalent radical derived by removal of a hydrogen atom from a 5 to 6-membered monocyclic heteroaromatic ring; the heterocyclic ring comprising one or more carbon atoms and 1 to 4 heteroatoms interconnected to form a ring.
  • the heteroatoms are independently selected from nitrogen, oxygen and sulphur.
  • Examples of monocyclic heteroaryl substituents are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, azepinyl, oxazepinyl, thiazepinyl and diazepinyl.
  • R-I is halo, C-
  • R ⁇ is halo or C-
  • R2 is H and R ⁇ is C-
  • R ⁇ is H and R ⁇ is C-
  • R ⁇ is H and R ⁇ is methyl. It will appreciated that in these latter embodiments, the carbon atom to which R ⁇ and R ⁇ are attached is chiral.
  • the scope of the present invention includes individual enantiomers and mixtures of each enantiomer including racemic mixtures.
  • the compound of formula (I) has formula (Ia)
  • Racemic compounds may either be separated using preparative HPLC and a column with a chiral stationary phase or resolved to yield individual enantiomers utilising methods known to those skilled in the art.
  • chiral intermediate compounds may be resolved and used to prepare chiral compounds of the invention.
  • the chiral compounds of the invention may be prepared by chiral synthesis.
  • R 4 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or phenyl, each of which is optionally substituted by one or more substituents independently selected from the list: halo; C-
  • R 4a and R 4 ⁇ which may be the same or different, are H or C- ⁇ galkyl
  • R 4c and R 4 ⁇ which may be the same or different, are H or C-
  • R 4e is C-
  • R 4 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or phenyl, each of which is optionally substituted by one or more substituents independently selected from the list: halo; C-
  • R 4 is pyridyl or phenyl, either of which is optionally substituted by one or more substituents independently selected from the list: halo; C-
  • ghaloalkylthio cyclopropyl; cyano; -N(R 4 a)(R 4 b); -C(O)N(R 4 C)(R 4 Cl); _ N(R 4C )C(O)R 4e ; -C(O)R 4e ; and -SO 2 R 4e ; wherein R 4a and R 4b , which may be the same or different, are H or C-
  • R 4 is pyridyl or phenyl, either of which is optionally substituted by one or more substituents independently selected from the list: halo; C-
  • R 4 is pyridyl or phenyl, either of which is optionally substituted by one or more substituents independently selected from the list: halo; C-
  • At least one of X and Y is N.
  • R x or RY is -(CH2) n R ⁇ , wherein R6 is 5- or 6-membered monocyclic heteroaryl or phenyl, either of which is optionally substituted by one or more substituents independently selected from the list: halo, C-
  • n is 0 or 1 ;
  • R ⁇ a and R ⁇ b which may be the same or different, are H or C-
  • R6C and R ⁇ d which may be the same or different, are H or C- ⁇ galkyl;
  • R 6e is C-
  • R x or RY is -(CH2) n R 6 , wherein R 6 is 5- or 6- membered monocyclic heteroaryl or phenyl, any of which is optionally substituted by one or more substituents independently selected from the list: halo, C- ⁇ galkyl and C-
  • R x or RY is -(CH2) n R ⁇ , wherein R ⁇ is pyridyl, phenyl, pyrazolyl, thienyl, thiazolyl or oxazolyl, any of which is optionally substituted by one or more substituents independently selected from the list: halo, C-
  • R x or RY is -(Ch ⁇ nR®.
  • R ⁇ is pyridyl, phenyl, pyrazolyl, thienyl, thiazolyl or oxazolyl, any of which is optionally substituted by one or more substituents independently selected from the list: halo, C-
  • the compounds of formula (I) are selected from the list consisting of:
  • the compounds of formula (I) as defined in the first aspect may contain a basic centre and may form non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids.
  • inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids.
  • Examples include the HCI, HBr, HI, sulfate or bisulfate, nitrate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, saccharate, fumarate, maleate, lactate, citrate, tartrate, gluconate, camsylate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate and pamoate salts.
  • suitable pharmaceutical salts see Berge et al, J.
  • the salt is pharmaceutically acceptable.
  • pro-drugs examples include Drugs of Today, Volume 19, Number 9, 1983, pp 499 - 538 and in Topics in Chemistry, Chapter 31 , pp 306 - 316 and in "Design of Prodrugs" by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference). It will further be appreciated by those skilled in the art, that certain moieties, known to those skilled in the art as “pro- moieties”, for example as described by H. Bundgaard in "Design of Prodrugs” (the disclosure in which document is incorporated herein by reference) may be placed on appropriate functionalities when such functionalities are present within the compounds defined in the first aspect.
  • the invention provides a prodrug of a compound defined in the first aspect.
  • the compounds defined in the first aspect, their salts or prodrugs, may exist in solvated or hydrated form. Therefore, in a further aspect, the invention provides a solvate or hydrate of a compound defined in the first aspect or a salt thereof.
  • the compounds of formula (I) defined in the first aspect or their salts, or solvates or hydrates of either, may exist in one or more polymorphic form. Therefore, in a further aspect, the invention provides a polymorph of a compound of formula (I) defined in the first aspect or their salts, or a polymorph of a solvate or hydrate of a compound of formula (I) defined in the first aspect, or a salt thereof.
  • compounds of formula (I) as defined in the first aspect their salts and prodrugs; any solvates or hydrates of any salt or prodrug; and any polymorph of any compound, salt, solvate or hydrate are referred to as "compounds of the invention”.
  • the term “compounds of the invention” also includes all embodiments of the first aspect.
  • the compounds of the invention may possess one or more chiral centres and so exist in a number of stereoisomeric forms. All stereoisomers and mixtures thereof are included in the scope of the present invention. Racemic compounds may either be separated using preparative HPLC and a column with a chiral stationary phase or resolved to yield individual enantiomers utilising methods known to those skilled in the art. In addition, chiral intermediate compounds may be resolved and used to prepare chiral compounds of the invention. In addition, the chiral compounds of the invention may be prepared by chiral synthesis.
  • the compounds of the invention may exist in one or more tautomeric forms. All tautomers and mixtures thereof are included in the scope of the present invention. For example, a claim to 2-hydroxyquinolinyl would also cover its tautomeric form, ⁇ - quinolinonyl.
  • the invention also includes all suitable isotopic variations of a compound of the invention.
  • An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 0, 31 P, 32 P, 35 S, 18 F and 36 CI, respectively.
  • isotopic variations of the invention are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances.
  • Isotopic variations of the compounds of the invention can generally be prepared by conventional procedures such as by the illustrative methods or by the preparations described in the Experimental section hereafter using appropriate isotopic variations of suitable reagents.
  • Compounds of formula (I) may be prepared by reacting compounds of formula (II) with activated carbamoyl reagents generated in s/fc/ from amines of formula (III) and a reagent such as carbonyl diimidazole (CDI) according to reaction scheme 1.
  • Typical reaction conditions comprise reacting (III) with CDI in a sealed vessel in a microwave reactor at 80 degC in dry DCM for 20 minutes followed by addition of (II) and further heating at 80 degC for 20 minutes.
  • compounds of formula (I) may be prepared by reacting compounds of formula (II) with isocyanates of formula (IV) according to reaction scheme 2.
  • Typical reaction conditions comprise reacting (II) with (IV) in a sealed vessel in a microwave reactor at 80 degC in dry DCM for 20 minutes.
  • Alternative conditions comprise reacting compounds of formula (II) with sodium hydride in THF at room temperature followed by addition of (IV) at room temperature.
  • Compounds of formula (II) may be prepared by reacting compounds of formula (V) with an organometallic reagent, such as an organolithium or a Grignard reagent, according to reaction scheme 3.
  • Typical reaction conditions comprise reacting (V) with Grignard reagent R ⁇ MgX in THF at room temperature.
  • Compounds of formula (Va), i.e. compounds of formula (V) where X is C(R X ), may be prepared by reacting compounds of formula (Vl) or their tautomers with compounds of formula (VII) according to reaction scheme 5.
  • Typical reaction conditions comprise reacting (Vl) with (VII) in a sealed vessel in a microwave reactor at 130 degC in ethanol for 20 minutes with or without a tertiary amine base (such as triethylamine).
  • compounds of formula (Vb) i.e. compounds of formula (V) (see scheme 3) where X is C(R X ) and R ⁇ is H, may be prepared according to reaction scheme 6, by reacting compounds of formula (Vl) or their tautomers with ⁇ -halo- ⁇ - keto esters of formula (VIII) to give compounds of formula (IX). Reduction of (IX) with lithium aluminium hydride followed by oxidation with manganese dioxide gives compounds of formula (Vb).
  • Compounds of formula (Via), i.e. compounds of formula (Vl) (see schemes 5 and 6) where X is -C(R X )- and Y is N, may be prepared according to reaction scheme 7 via compounds of formula (X).
  • Compounds of formula (X) may be prepared by reacting activated carboxylic acids (Xl) (such as acid chlorides and 1-hydroxybenzotriazole esters) with a thiosemicarbazide.
  • Typical reaction conditions comprise reacting compounds of formula (Xl) with the thiosemicarbazide in a sealed vessel in a microwave reactor at 80 degC in a suitable solvent (such as DCM or acetone) for 10 minutes with or without a tertiary amine base (such as triethylamine) to give (X).
  • a suitable solvent such as DCM or acetone
  • a tertiary amine base such as triethylamine
  • Cyclisation of (X) to give (Via) may be achieved by reacting (X) in a sealed vessel in a microwave reactor at 150 degC in aqueous ethanolic sodium hydroxide for 10 minutes.
  • the compounds of the invention antagonise the mGluR5 receptor and may be used to treat diseases or conditions wherein antagonism of the mGluR5 receptor is beneficial. Therefore according to a further aspect, the invention provides a compound of the invention for use in treating a disease or condition.
  • the disease or condition is a human disease or condition.
  • the disease or condition is one wherein antagonism of the mGluR5 receptor is beneficial.
  • the disease or condition wherein antagonism of the mGluR5 receptor is beneficial is selected from the list consisting of: [the numbers in brackets after the listed diseases below refer to the classification code in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM-IV) and/or the International Classification of Diseases, 10th Edition (ICD-10)]:
  • i) Psychotic disorders for example Schizophrenia (including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60)); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) (including the subtypes Bipolar Type and Depressive Type); Delusional Disorder (297.1) (including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type); Brief Psychotic Disorder (298.8); Shared
  • Psychotic Disorder 297.3
  • Psychotic Disorder due to a General Medical Condition including the subtypes with Delusions and with Hallucinations
  • Substance-Induced Psychotic Disorder including the subtypes with Delusions (293.81 ) and with Hallucinations (293.82)
  • Psychotic Disorder Not Otherwise Specified 298.9
  • Depression and mood disorders for example Depressive Episodes (including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode); Depressive Disorders (including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (31 1 )); Bipolar Disorders (including Bipolar I Disorder, Bipolar Il Disorder (i.e.
  • Anxiety disorders for example Social Anxiety Disorder; Panic Attack; Agoraphobia, Panic Disorder; Agoraphobia Without History of Panic Disorder (300.22); Specific Phobia (300.29) (including the subtypes Animal Type, Natural Environment Type, Blood-lnjection-lnjury Type, Situational Type and Other Type); Social Phobia (300.23); Obsessive-Compulsive Disorder (300.3); Posttraumatic Stress Disorder (309.81 ); Acute Stress Disorder (308.3); Generalized Anxiety Disorder (300.02); Anxiety Disorder Due to a General Medical Condition (293.84); Substance-Induced Anxiety Disorder; and Anxiety Disorder Not Otherwise Specified (300.00).
  • Substance-related disorders for example Substance Use Disorders (including Substance Dependence, Substance Craving and Substance Abuse); Substance- Induced Disorders (including Substance Intoxication, Substance Withdrawal,
  • Phencyclidine or Phencyclidine-Like)-Related Disorders (including Phencyclidine Dependence (304.60), Phencyclidine Abuse (305.90), Phencyclidine Intoxication (292.89), Phencyclidine Intoxication Delirium, Phencyclidine-lnduced Psychotic Disorder, Phencyclidine-lnduced Mood Disorder, Phencyclidine-lnduced Anxiety Disorder and Phencyclidine-Related Disorder Not Otherwise Specified (292.9)); Phencyclidine (or Phencyclidine-Like)-Related Disorders (including Phencyclidine Dependence (304.60), Phencyclidine Abuse (305.90), Phencyclidine Intoxication (292.89), Phencyclidine Intoxication Delirium, Phencyclidine-lnduced Psychotic Disorder, Phencyclidine-lnduced Mood Disorder, Phencyclidine-lnduced Anxiety Disorder and Phencyclidine-Related Disorder Not Otherwise Specified (292.9)); Ph
  • Sleep disorders for example primary sleep disorders such as Dyssomnias
  • Eating disorders such as Anorexia Nervosa (307.1 ) (including the subtypes Restricting Type and Binge-Eating/Purging Type); Bulimia Nervosa (307.51 ) (including the subtypes Purging Type and Nonpurging Type); Obesity; Compulsive Eating Disorder; Binge Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
  • Anorexia Nervosa (307.1 ) (including the subtypes Restricting Type and Binge-Eating/Purging Type); Bulimia Nervosa (307.51 ) (including the subtypes Purging Type and Nonpurging Type); Obesity; Compulsive Eating Disorder; Binge Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50).
  • Autism Spectrum Disorders including Autistic Disorder (299.00), Asperger's Disorder, Rett's Disorder, Childhood Disintegrative Disorder and Pervasive Developmental Disorder Not Otherwise Specified.
  • Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Deficit /Hyperactivity Disorder Combined Type (314.01 ), Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit/Hyperactivity Disorder Hyperactive-Impulse Type (314.01 ) and Attention-Deficit/Hyperactivity Disorder Not Otherwise Specified (314.9)); Hyperkinetic Disorder; Disruptive
  • Behaviour Disorders such as Conduct Disorder (including the subtypes childhood- onset type (321.81 ), Adolescent-Onset Type (312.82) and Unspecified Onset (312.89), Oppositional Defiant Disorder (313.81 ) and Disruptive Behaviour Disorder
  • Tic Disorders such as Tourette's Disorder (307.23).
  • Enhancement of cognition including the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment, e.g. Alzheimer's disease.
  • the disease or condition wherein antagonism of the mGluR5 receptor is beneficial is selected from the list consisting of: Parkinson's Disease, epilepsy, inflammatory pain, neuropathic pain, migraine, Down's Syndrome and gastroesophageal reflux disease.
  • the invention provides a compound of the invention for use as a neuroprotectant.
  • the disease or condition wherein antagonism of the mGluR5 receptor is beneficial is a substance-related disorder.
  • references herein to "treat”, “treating” or “treatment” extend to prophylaxis, prevention of recurrence and suppression or amelioration of symptoms (whether mild, moderate or severe) as well as the treatment of established conditions.
  • a compound of the invention in the manufacture of a medicament for treating a disease or condition wherein antagonism of the mGluR5 receptor is beneficial.
  • the disease or condition is a substance related disorder.
  • ii) A method of treating a disease or condition wherein antagonism of the mGluR5 receptor is beneficial in a mammal comprising administering an effective amount of a compound of the invention.
  • the disease or condition is a substance related disorder.
  • the compounds of the invention will normally, but not necessarily, be formulated into pharmaceutical compositions prior to administration to a patient by an appropriate route. Accordingly, in another aspect, the invention provides pharmaceutical compositions comprising a compound of the invention and one or more pharmaceutically-acceptable excipients.
  • pharmaceutically-acceptable excipient means any pharmaceutically acceptable material present in the pharmaceutical composition or dosage form other than the compound or compounds of the invention. Typically the material gives form, consistency and performance to the pharmaceutical composition.
  • the pharmaceutical compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may comprise one or more additional pharmaceutically active compounds.
  • compositions of the invention may be prepared and packaged in bulk form wherein a safe and effective amount of a compound of the invention can be dispensed and then given to the patient such as with powders or syrups.
  • the pharmaceutical compositions of the invention may be prepared and packaged as dosage forms wherein each physically discrete dosage form contains a safe and effective amount of a compound of the invention.
  • the invention provides dosage forms comprising pharmaceutical compositions of the invention. Each discrete dosage form typically contains from 0.1 mg to 100 mg of a compound of the invention.
  • compositions of the invention will typically be formulated into dosage forms which are adapted for administration to the patient by the desired route of administration.
  • dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, lozenges, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets and cachets; (2) parenteral administration such as sterile solutions, suspensions, implants and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal and vaginal administration such as suppositories, pessaries and foams; (5) inhalation and intranasal such as dry powders, aerosols, suspensions and solutions (sprays and drops); (6) topical administration such as creams, ointments, lotions, solutions, pastes, drops, sprays, foams and gels; (7) ocular administration such as drops, ointment, sprays, suspensions and inserts; (8) buccal and sub
  • Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the release of the compound of the invention at the appropriate rate to treat the condition.
  • Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavouring agents, flavour masking agents, colouring agents, anticaking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, rate modifying agents, antioxidants, preservatives, stabilizers, surfactants and buffering agents.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavouring agents, flavour masking agents, colouring agents, anticaking agents, hume
  • Skilled artisans possess the knowledge and skill in the art to enable them to determine suitable pharmaceutically-acceptable excipients in appropriate amounts for use with the compounds of the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically- acceptable excipients and may be useful in selecting suitable pharmaceutically- acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • the pharmaceutical compositions of the invention may be prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a safe and effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include starches, crospovidone, sodium starch glycolate, cros- carmellose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and sodium dodecyl sulphate.
  • the oral solid dosage form may further comprise a glidant such as talc and colloidal silicon dioxide.
  • the oral solid dosage form may further comprise an outer coating which may have cosmetic or functional properties.
  • the compounds of the invention may be used in combination with the following agents to treat or prevent psychotic disorders: i) antipsychotics; ii) drugs for extrapyramidal side effects, for example anticholinergics (such as benztropine, biperiden, procyclidine and trihexyphenidyl), antihistamines (such as diphenhydramine) and dopaminergics (such as amantadine); iii) antidepressants; iv) anxiolytics; and v) cognitive enhancers for example cholinesterase inhibitors (such as tacrine, donepezil, rivastigmine and galantamine).
  • anticholinergics such as benztropine, biperiden, procyclidine and trihexyphenidyl
  • antihistamines such as diphenhydramine
  • dopaminergics such as amantadine
  • antidepressants such as amantadine
  • iv) anxiolytics such as anxio
  • the compounds of the invention may be used in combination with antidepressants to treat or prevent depression and mood disorders.
  • the compounds of the invention may be used in combination with the following agents to treat or prevent bipolar disease: i) mood stabilisers; ii) antipsychotics; and iii) antidepressants.
  • the compounds of the invention may be used in combination with the following agents to treat or prevent anxiety disorders: i) anxiolytics; and ii) antidepressants.
  • Antipsychotic drugs include Typical Antipsychotics (for example chlorpromazine, thioridazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, trifluoperazine, thiothixine, haloperidol, molindone and loxapine); and Atypical Antipsychotics (for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone and amisulpride).
  • Typical Antipsychotics for example chlorpromazine, thioridazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, trifluoperazine, thiothixine, haloperidol, molindone and loxapine
  • Atypical Antipsychotics for example clozapine, olanzapine, risperidone, quetiapine,
  • Antidepressant drugs include serotonin reuptake inhibitors (such as citalopram, escitalopram, fluoxetine, paroxetine, sertraline femoxetine, fluvoxamine, indalpine and zimeldine); dual serotonin/noradrenaline reuptake inhibitors (such as venlafaxine, duloxetine and milnacipran); Noradrenaline reuptake inhibitors (such as reboxetine and venlafaxine); tricyclic antidepressants (such as amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline and trimipramine); monoamine oxidase inhibitors (such as isocarboxazide, moclobemide, phenelzine and tranylcypromine); and others (such as bupropion, mianserin, mirtazapine, nefazodone and trazodone).
  • Mood stabiliser drugs include lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate and tiagabine.
  • Anxiolytics include benzodiazepines such as alprazolam and lorazepam.
  • the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.
  • TLC preparative plates Silica gel on glass, 1000 ⁇ m, 20x20 cm
  • Aldrich commercially available from Aldrich
  • hydrophobic cartridges Isolute Phase Separators
  • propylsulfonic acid functionalized silica cartridges IOLUTE SCX-2
  • a number of the compounds were purified using a Mass Directed Auto-Purification System (MDAP) incorporating HPLC techniques and an appropriate mass spectrometer such as the Waters® ZQ mass spectrometer.
  • MDAP Mass Directed Auto-Purification System
  • Microwave heating was performed using InitiatorTM and EmrysTM Optimizer microwave reactors from Biotage.
  • Phenyl isocyanate (0.040 ml, 0.363 mmol) was added to (+/-) 1-[6-methyl-2-(3- pyridinyl)[1 ,3]thiazolo[3,2- ⁇ b][1 ,2,4]triazol-5-yl]ethanol (Intermediate 1 ) (18.9 mg, 0.073 mmol) in DCM (4 ml) and TEA (0.020 ml, 0.145 mmol). The reaction mixture was heated in a microwave reactor at 80 0 C for 20min. After solvent removal, the crude material was purified by MDAP.
  • Ci 9 H 17 N 5 O 2 S requires 379 ( analysesd by LCMS A); 1 H NMR (400 MHz, CDCL 3 ): ⁇ 9.40 (1 H, dd), 8.66 (1 H, dd), 8.42 (1 H, dt), 7.41-7.29 (5H, m), 7.08 (1 H, t), 6.85 (1 H, broad s), 6.24 (1 H, q), 2.69 (3H, s), 1.71 (3H, d).
  • the supporting compounds were tested in one of the following calcium mobilisation assays.
  • the growth media comprised DMEM (Dulbeccos Modifies Eagle medium) 50OmIs (supplied by Gibco - catalogue number 31 166), 50 ml dialysed FCS (Foetal Calf Serum) (supplied by Gibco - catalogue number 26400-044), 0.02mg/ml proline, 0.25mg/ml hygromycin and 0.5mg/ml zeocin.
  • the cells in the growth media were then dispensed using a Multidrop (supplied by ThermoFisher) into 384-well black clear-bottom plates at a confluency of 1 OK cells/well in a volume of 50 ⁇ l. The plates were incubated at 37 0 C to give a monolayer with a confluency of 80%.
  • the growth medium was aspirated using a power washer (supplied by Tecan) and 30 ⁇ l of loading buffer was added to the cells using a Multidrop.
  • the loading buffer comprised Hanks Balanced Salt Solution (HBSS) + 2.5M probenicid + 2 ⁇ M Fluo-4 (MDC) and 250 ⁇ M Brilliant Black (MDC).
  • HBSS Hanks Balanced Salt Solution
  • MDC 2 ⁇ M Fluo-4
  • MDC 250 ⁇ M Brilliant Black
  • test compounds in DMSO at a concentration of 1 OmM, were further diluted with DMSO using a Biomek FX (supplied by Beckman Coulter) into a 384-well compound plate (supplied by Greiner). Each dilution was then transferred in 1 ul aliquots to a further compound plate and assay buffer added to give a final volume of 50 ⁇ l, making a final assay concentration of 1 1.8 ⁇ M.
  • the assay buffer consisted of HBSS and 2.5M probenicid.
  • a 0.38M solution of glutamic acid in water was further diluted in DMSO to a concentration of 204 mM.
  • 16 x 1 1 point concentration response curves (CRCs) were prepared in DMSO with a top concentration of 204mM, making the final assay concentration 1 mM, diluted serially to 1 in 4. This was performed using the Biomek FX liquid handling device. 1 ⁇ l stampouts of the CRCs were prepared. 50 ⁇ l of compound buffer was added prior to use.
  • test compounds 10 ⁇ l were added to the cell plates using a Cybiwell liquid handling device (supplied by Cybio). The cell plates were incubated at 37 0 C for 15 min, a FLIPR addition of the EC80 was made and a fluorescent read generated. Blocking of the receptor by test compound, in a dose dependent manner is evident from the calcium vs time profiles generated for each well. The data is analysed using XC50 software to produce CRCs, from which the potency and plC50 can be determined.
  • CHO cells containing human mGluR ⁇ receptors with Tet On expression control technology (supplied by Clontech) were prepared. These cells were grown in cell factories, induced with 10ng/ml doxycycline to enable expression, harvested and then cryo-preserved at -140 0 C in 1 ml aliquots for future use.
  • the cells were thawed, suspended in growth media and centrifuged at I OOOrpm for 5 min.
  • the growth media consisted of F12 Hams Nutrient mix (supplied by Gibco - catalogue number 21765) and 10% Tet approved FBS (supplied by Clontech - catalogue number 631 106). The cells were then re-suspended in growth media and incubated at 37°C for 1 hour in a spinner flask.
  • the cell suspension was centrifuged once more and resuspended at 2.5 x 10 ⁇ cells/ml in loading buffer consisting of HBSS, 0.1 % BSA (supplied by CalBiochem - catalogue number 126609) and 0.1 % Pluronic F68 (supplied by Gibco - catalogue number 24040-032).
  • the cells were loaded with coelentrazine (supplied by Invitrogen C - catalogue number 6780) to a concentration of 5 ⁇ M, wrapped in foil and loaded overnight with mixing.
  • the cells were diluted to 15 x 10 ⁇ cells/ml in dilution buffer consisting of HBSS and 0.1 % Pluronic F68.
  • Coelentrazine is the chromophore co-factor which activates the apo-protein, aequorin.
  • the protein has three high affinity binding sites for calcium.
  • agonism of the mGluR ⁇ receptor binding of calcium to the aequorin protein induces a conformational change resulting in an oxidative decarboxylation reaction producing coelenteramide and a flash luminescence signal. This signal was measured using the Lumilux (supplied by Perkin Elmer).
  • test compounds were prepared in DMSO at a concentration of 3mM. These solutions are serially diluted with DMSO to 1 in 4 using a Biomek FX liquid handling device (supplied by Beckman Coulter) in a 384-well compound plate (supplied by Greiner). Daughter plates of 0.5 ⁇ l/well were stamped-out from this master plate for use in the assay.
  • Glutamate Dose Response Curve Preparation A 10OmM solution of glutamic acid was prepared in water. This was further diluted with DMSO to a concentration of 1OmM. 16 x 11 point concentration response curves (CRC) were prepared in DMSO, making the final assay concentration 1.66 xi O ' ⁇ M, with 1 in 3 serial dilutions using the Biomek FX. 0.5 ⁇ l stamp-outs of this plate were generated for use in the assay.
  • CRC concentration response curves
  • the glutamate CRC plate was placed on the Lumilux where 20 ⁇ l/well of dilution buffer was added, followed by 10 ⁇ l/well of loaded cell suspension and a luminescence read was made.
  • An EC80 concentration of glutamate was calculated by using 4X EC50 generated.
  • the EC80 solution was prepared in dilution buffer and added to a reservoir within the Lumilux.
  • the supporting compounds were tested in assay a) and/or assay b). Using assay b) all supporting compounds gave a plC50 equal to or greater than 5.5.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention porte sur de nouveaux dérivés de thiazoltriazole et de thiazolimidazole représentés par la formule (I). L'invention porte également sur l'utilisation des dérivés dans le traitement de maladies et d'états dans lesquels l'antagonisme du récepteur mGluR5 est avantageux, en particulier de troubles se rapportant à une substance. De plus, l'invention porte sur des compositions contenant les dérivés et sur des procédés permettant de les préparer.
PCT/EP2009/050215 2008-01-10 2009-01-09 Thiazoltriazoles et thiazolimidazoles comme antagonistes du récepteur mglur5 WO2009087218A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0800411.1 2008-01-10
GBGB0800411.1A GB0800411D0 (en) 2008-01-10 2008-01-10 Novel compounds

Publications (1)

Publication Number Publication Date
WO2009087218A1 true WO2009087218A1 (fr) 2009-07-16

Family

ID=39144721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/050215 WO2009087218A1 (fr) 2008-01-10 2009-01-09 Thiazoltriazoles et thiazolimidazoles comme antagonistes du récepteur mglur5

Country Status (2)

Country Link
GB (1) GB0800411D0 (fr)
WO (1) WO2009087218A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072697A1 (fr) 2009-12-17 2011-06-23 H. Lundbeck A/S Dérivés hétéroaromatiques d'aryltriazole en tant qu'inhibiteurs de l'enzyme pde10a
CN104892640A (zh) * 2015-05-28 2015-09-09 石家庄学院 2-苯基-6-苯甲酰基-噻唑并[3,2-b][1,2,4]-三氮唑类衍生物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167369A1 (fr) * 1999-04-06 2002-01-02 Yamanouchi Pharmaceutical Co. Ltd. Nouveaux derives de thiazolobenzimidazole
WO2006074884A1 (fr) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Derives de thiazole-4-carboxamide en tant qu'antagonistes du mglur5
WO2007054436A2 (fr) * 2005-11-08 2007-05-18 F. Hoffmann-La Roche Ag Derives la thiazolo[4,5-c]pyridine en tant qu'antagonistes du recepteur mglur5

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167369A1 (fr) * 1999-04-06 2002-01-02 Yamanouchi Pharmaceutical Co. Ltd. Nouveaux derives de thiazolobenzimidazole
WO2006074884A1 (fr) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Derives de thiazole-4-carboxamide en tant qu'antagonistes du mglur5
WO2007054436A2 (fr) * 2005-11-08 2007-05-18 F. Hoffmann-La Roche Ag Derives la thiazolo[4,5-c]pyridine en tant qu'antagonistes du recepteur mglur5

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072697A1 (fr) 2009-12-17 2011-06-23 H. Lundbeck A/S Dérivés hétéroaromatiques d'aryltriazole en tant qu'inhibiteurs de l'enzyme pde10a
CN104892640A (zh) * 2015-05-28 2015-09-09 石家庄学院 2-苯基-6-苯甲酰基-噻唑并[3,2-b][1,2,4]-三氮唑类衍生物及应用

Also Published As

Publication number Publication date
GB0800411D0 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
EP2279184B1 (fr) Indoles utilisés en tant que modulateurs du sous-type alpha-7 du récepteur nicotinique de l'acétylcholine
JP5820537B2 (ja) Ｍｇｌｕ５受容体モジュレータとしての置換ピラゾール
JP6325449B2 (ja) シクロプロパンアミン化合物およびその用途
JP6111195B2 (ja) シクロプロパンアミン化合物
AU2011322562B2 (en) Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or Alzheimer's disease
TWI543974B (zh) 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途
AU2009246424A1 (en) Glucagon receptor antagonists, compositions, and methods for their use
EP2488514B1 (fr) Modulateurs indoles et azaindoles du nachr- 7
EP2516437A1 (fr) Pyridines accolées à di-substitution hétéroaryle
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
US20110065725A1 (en) Triazole amide derivatives for use in therapy
JPH04234860A (ja) チアジン（又はオキサジン）誘導体、その製法及びその合成中間体
WO2011151361A1 (fr) Nouveaux composés
JP2010504367A (ja) 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体
EP1664063A1 (fr) Piperazines substitutees d'azepines, d'oxazepines, et de thiazepines
WO2009087218A1 (fr) Thiazoltriazoles et thiazolimidazoles comme antagonistes du récepteur mglur5
WO2009087220A1 (fr) Utilisation de thiazoloimidazoles, de thiazolotétrazoles et de thiazolotriazoles comme antagonistes de mglur5
SG175084A1 (en) Indole derivative modulators of the alpha 7 nachr
WO2010142652A1 (fr) Composés imidazobenzazépine pour le traitement des maladies du système nerveux central (snc)
WO2008122561A1 (fr) Dérivé de pyridinone pour traiter l'éjaculation précoce
US20100311734A1 (en) Spiro Compounds Useful as Antagonists of the H1 Receptor
JP2020519694A (ja) オレキシン受容体アンタゴニス
TW200911234A (en) Compounds which inhibit the glycine transporter and uses thereof in medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09701348

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09701348

Country of ref document: EP

Kind code of ref document: A1